C. Libanati

发表

Administration of romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative computed tomography and finite element analysis.

C. Graeff, C. Glüer, J. Borggrefe, 2015, Bone.

Comparison of proximal femur and vertebral body strength improvements in the FREEDOM trial using an alternative finite element methodology.

H. Genant, P. Zysset, K. Engelke, 2015, Bone.

Advanced CT based In Vivo Methods for the Assessment of Bone Density, Structure, and Strength

H. Genant, P. Zysset, T. Fuerst, 2013, Current Osteoporosis Reports.

Quantitative computed tomography (QCT) of the forearm using general purpose spiral whole-body CT scanners: accuracy, precision and comparison with dual-energy X-ray absorptiometry (DXA).

Klaus Engelke, Cesar Libanati, Wolfram Timm, 2009, Bone.

Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

Claus Christiansen, Cesar Libanati, Michael R McClung, 2009, The New England journal of medicine.

Strength training increases regional bone mineral density and bone remodeling in middle-aged and older men.

B. Hurley, R. Pratley, J. Hagberg, 1993, Journal of applied physiology.

National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges

S. Silverman, H. Vesper, N. Lane, 2012, Osteoporosis International.

Fixation of humeral prostheses and axial micromotion.

Q. Dai, C. Libanati, T. Peppers, 1998, Journal of shoulder and elbow surgery.

Sustained Modeling‐Based Bone Formation During Adulthood in Cynomolgus Monkeys May Contribute to Continuous BMD Gains With Denosumab

P. Kostenuik, R. Baron, D. Dempster, 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab

A. Grauer, N. Lane, Toshio Matsumoto, 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture

J. Adachi, E. Franek, M. McClung, 2012, Menopause.

Response to: Comment on: “Denosumab Rapidly Increases Cortical Bone in Key Locations of the Femur: A 3D Bone Mapping Study in Women With Osteoporosis”

Graham M. Treece, Jacques P. Brown, A. Gee, 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab.

H. Genant, T. Fuerst, K. Engelke, 2013, Bone.

A novel economic framework to assess the cost-effectiveness of bone-forming agents in the prevention of fractures in patients with osteoporosis

J. Kanis, M. Charokopou, C. Libanati, 2021, Osteoporosis International.

Imminent fracture risk assessments in the UK FLS setting: implications and challenges

C. Cooper, M. Javaid, M. Charokopou, 2019, Archives of Osteoporosis.

Acute Effects of Calcitonin Nasal Spray on Serum C-telopeptide of Type 1 Collagen (CTx) Levels in Elderly Osteopenic Women with Increased Bone Turnover

A. Kriegman, C. Libanati, D. Baylink, 2004, Calcified Tissue International.

Comorbidity indices for clinical trials: adaptation of two existing indices for use with the FREEDOM trial in women with postmenopausal osteoporosis

S. Silverman, M. Nevitt, D. Revicki, 2015, Osteoporosis International.

Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial.

S. Cummings, M. Bhandari, S. Boonen, 2012, The Journal of bone and joint surgery. American volume.

Vrije Universiteit Brussel Detection of vertebral fractures in CT using 3D Convolutional Neural Networks

D. Vandermeulen, D. Robben, C. Libanati, 2019 .

One- and 2-year incidence of osteoporotic fracture: a multi-cohort observational study using routinely collected real-world data

B. Abrahamsen, D. Prieto-Alhambra, C. Libanati, 2021, Osteoporosis International.

Spinal fractures during fluoride therapy for osteoporosis: Relationship to spinal bone density

R. Cruise, J. Wergedal, C. Libanati, 1992, Osteoporosis International.

Skeletal ScintigraphicChanges in OsteoporosisTreated with Sodium Fluoride : ConciseCommunication

C. Libanati, E. Schulz, G. Kirk, 2006 .

Fluoride therapy for osteoporosis promotes a progressive increase in spinal bone density

C. Libanati, E. Schulz, D. Baylink, 1990, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Efficacy of long-term fluoride and calcium therapy in correcting the deficit of spinal bone density in osteoporosis.

C. Libanati, E. Schulz, D. Baylink, 1989, Journal of clinical epidemiology.

Association between transitory increase in PTH following denosumab administration and reduced intracortical porosity is a distinctive attribute of denosumab therapy

A. Grauer, J. Bilezikian, J. Zanchetta, 2012 .

Modeling‐Based Bone Formation After 2 Months of Romosozumab Treatment: Results From the FRAME Clinical Trial

Jacques P. Brown, R. Chapurlat, P. Chavassieux, 2021, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

The treatment gap after major osteoporotic fractures in Denmark 2005-2014: a combined analysis including both prescription-based and hospital-administered anti-osteoporosis medications

C. Cooper, M. Javaid, B. Abrahamsen, 2021, Osteoporosis International.

History of Previous Fracture and Imminent Fracture Risk in Swedish Women Aged 55 to 90 Years Presenting With a Fragility Fracture

C. Libanati, K. Akesson, A. Spångeus, 2020, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Romosozumab and antiresorptive treatment: the importance of treatment sequence

E. Lewiecki, C. Libanati, D. Kendler, 2022, Osteoporosis International.

Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis

M. Brandi, D. Hans, J. Zanchetta, 2017, Osteoporosis International.

T‐Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial

P. Ebeling, Toshio Matsumoto, N. Napoli, 2020, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Unmasking romosozumab: response to commentsby Uzoigwe et al.

C. Libanati, F. Cosman, D. Crittenden, 2017, Osteoporosis International.

Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals

S. Cummings, E. Lespessailles, F. Bertoldo, 2021, JBMR plus.

Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis.

J. P. Perez Ruixo, J. Mandema, C. Libanati, 2014, The Journal of clinical endocrinology and metabolism.

Analytical and clinical evaluation of the Bio-Rad HPLC kit for measurement of type I collagen cross links

M. Greenwald, C. Libanati, D. Baylink, 2003, Journal of Bone and Mineral Metabolism.

Effect of a Weight‐Reduction Program on Total and Regional Body Composition in Obese Postmenopausal Women

T. Lohman, W. Howell, C. Libanati, 2000, Annals of the New York Academy of Sciences.

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial

Jacques P. Brown, H. Genant, A. Grauer, 2017, The Lancet.

Effects of strength training on bone mineral density: hormonal and bone turnover relationships.

J. P. Miller, B. Nicklas, J. Miller, 1994, Journal of applied physiology.

Prevention and treatment of glucocorticoid-induced osteoporosis. A pathogenetic perspective.

C. Libanati, D. Baylink, 1992, Chest.

Biochemical markers of bone turnover for the clinical assessment of bone metabolism.

C. Libanati, D. Baylink, A. K. Taylor, 1994, Rheumatic diseases clinics of North America.

Vertebral bone density in children: effect of puberty.

M. Boechat, V. Gilsanz, C. Libanati, 1988, Radiology.

Romosozumab efficacy and safety in European patients enrolled in the FRAME trial

A. Fahrleitner-Pammer, B. Langdahl, C. Libanati, 2022, Osteoporosis International.

Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab

A. Grauer, R. Dinavahi, C. Libanati, 2019, Osteoporosis International.

Development, validation, and application of a radioimmunoassay for insulin-like growth factor binding protein-5 in human serum and other biological fluids.

S. Mohan, C. Libanati, D. Baylink, 1995, The Journal of clinical endocrinology and metabolism.

Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate.

D. Felsenberg, P. Miller, E. Lewiecki, 2008, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

OP0248 Inhibition of Sclerostin with Romosozumab in Postmenopausal Women with Low Bone Mineral Density: Phase 2 Trial Results

Jacques P. Brown, S. Boonen, A. Díez-Pérez, 2013 .

Skeletal responses to romosozumab after 12 months of denosumab

Jacques P. Brown, J. Reginster, A. Chines, 2021, JBMR plus.

Evidence that fluoride therapy increases trabecular bone density in a peripheral skeletal site.

P. Bettica, C. Libanati, E. Schulz, 1993, The Journal of clinical endocrinology and metabolism.

Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal.

J. Wergedal, F. Vanhoenacker, W. Van Hul, 2003, The Journal of clinical endocrinology and metabolism.

Osteogenic Actions of Fluoride: Its Therapeutic Use for Established Osteoporosis

K. Lau, C. Libanati, D. Baylink, 2013 .

Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial

Jacques P. Brown, D. Kiel, R. Recker, 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Romosozumab Treatment in Postmenopausal Women with Osteoporosis.

A. Grauer, L. Hofbauer, E. Lau, 2016, The New England journal of medicine.

Estimating the Incidence and Key Risk Factors of Cardiovascular Disease in Patients at High Risk of Imminent Fracture Using Routinely Collected Real‐World Data From the UK

D. Prieto-Alhambra, C. Libanati, A. Delmestri, 2022, medRxiv.

Denosumab Rapidly Increases Cortical Bone in Key Locations of the Femur: A 3D Bone Mapping Study in Women With Osteoporosis

Andrew H Gee, Graham M Treece, Graham M. Treece, 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.

A. Grauer, C. Libanati, A. Miyauchi, 2017, Bone.

Romosozumab in postmenopausal women with low bone mineral density

Cesar Libanati, Steven Boonen, Michael R McClung, 2014, The New England journal of medicine.

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study

J. Reginster, C. Roux, E. Franek, 2015, Osteoporosis International.

Total Hip Bone Mineral Density as an Indicator of Fracture Risk in Bisphosphonate‐Treated Patients in a Real‐World Setting

A. Moayyeri, C. Libanati, A. Spångeus, 2021, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Skeletal scintigraphic changes in osteoporosis treated with sodium fluoride: concise communication.

C. Libanati, E. Schulz, D. Baylink, 1984, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

The Effect of 1 Year of Romosozumab on the Incidence of Clinical Vertebral Fractures in Postmenopausal Women With Osteoporosis: Results From the FRAME Study

P. Geusens, A. Grauer, J. Adachi, 2019, JBMR plus.

Effects of denosumab on bone turnover markers in postmenopausal osteoporosis

S. Cummings, C. Christiansen, I. Reid, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Bone‐Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment

Jacques P. Brown, A. Grauer, R. Chapurlat, 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study

A. Grauer, J. Adachi, P. Ebeling, 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX

J. Kanis, E. McCloskey, E. Siris, 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Comparison of body composition by bioelectrical impedance and dual-energy x-ray absorptiometry in overweight/obese postmenopausal women.

C. Libanati, L. Beeson, Dina H. Fakhrawi, 2009, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Differing effects of denosumab and alendronate on cortical and trabecular bone.

Ego Seeman, Stephanie Boutroy, Cesar Libanati, 2014, Bone.

Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass

Klaus Engelke, Thomas Fuerst, Cesar Libanati, 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures

S. Cummings, C. Christiansen, E. Vittinghoff, 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Risk of imminent fracture following a previous fracture in a Swedish database study

K. Åkesson, Ö. Ljunggren, O. Ljunggren, 2019, Osteoporosis International.

Denosumab significantly increases DXA BMD at both trabecular and cortical sites: results from the FREEDOM study.

M. Brandi, P. Lakatos, A. Høiseth, 2011, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Romosozumab Improves Lumbar Spine Bone Mass and Bone Strength Parameters Relative to Alendronate in Postmenopausal Women: Results From the ARCH Trial.

Jacques P. Brown, T. Keaveny, K. Engelke, 2021, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Femoral and Vertebral Strength Improvements in Postmenopausal Women With Osteoporosis Treated With Denosumab

Jacques P. Brown, H. Genant, R. Eastell, 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Secular trends in the initiation of therapy in secondary fracture prevention in Europe: a multi-national cohort study including data from Denmark, Catalonia, and the United Kingdom

C. Cooper, M. Javaid, B. Abrahamsen, 2020, Osteoporosis International.

Hip mineral density in females with a recent hip fracture.

C. Libanati, E. Schulz, D. Baylink, 1992, The Journal of clinical endocrinology and metabolism.

Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome

A. Grauer, E. Lewiecki, S. Ferrari, 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Risk of major osteoporotic fracture after first, second and third fracture in Swedish women aged 50 years and older.

M. Charokopou, C. Libanati, O. Ström, 2020, Bone.

Denosumab Reduces Cortical Porosity of the Proximal Femoral Shaft in Postmenopausal Women With Osteoporosis

A. Høiseth, J. Zanchetta, M. McClung, 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

S. Mohan, C. Libanati, D. Baylink, 2022 .

Importance of Time Point-Specific Indirect Treatment Comparisons of Osteoporosis Treatments: A Systematic Literature Review and Network Meta-Analyses.

M. Javaid, M. Charokopou, C. Libanati, 2022, Clinical therapeutics.

Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group

J. Bilezikian, P. Miller, P. Ebeling, 2019, Osteoporosis International.

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years

J. Reginster, C. O’Malley, J. Adachi, 2015, Osteoporosis International.

Microarchitectural deterioration of cortical and trabecular bone: Differing effects of denosumab and alendronate

Sharmila Majumdar, Ego Seeman, Stephanie Boutroy, 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Racial differences in bone density between young adult black and white subjects persist after adjustment for anthropometric, lifestyle, and biochemical differences.

S. Cummings, S. Sidney, B. Ettinger, 1997, The Journal of clinical endocrinology and metabolism.

Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density.

H. Genant, T. Fuerst, K. Engelke, 2010, Bone.

Greater Gains in Spine and Hip Strength for Romosozumab Compared With Teriparatide in Postmenopausal Women With Low Bone Mass

Jacques P. Brown, H. Genant, A. Grauer, 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active‐Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial

Jacques P. Brown, T. Keaveny, K. Engelke, 2021, Journal of Bone and Mineral Research.

Relationship Between Bone Mineral Density T‐Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment

J. Reginster, E. Lewiecki, C. Libanati, 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Romosozumab followed by denosumab in Japanese women with high fracture risk in the FRAME trial

C. Libanati, A. Miyauchi, Junichiro Shimauchi, 2020, Journal of Bone and Mineral Metabolism.

Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension

A. Grauer, R. Dinavahi, C. Libanati, 2019, Archives of Osteoporosis.

Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial

A. Grauer, R. Dinavahi, T. Hirama, 2019, Journal of Bone and Mineral Metabolism.

Denosumab for prevention of fractures in postmenopausal women with osteoporosis. Editorial comment

C. Christiansen, R. Eastell, P. Delmas, 2009 .

Development of a synthetic peptide-based tartrate-resistant acid phosphatase radioimmunoassay for the measurement of bone resorption in rat serum

N. Lane, C. Libanati, D. Baylink, 2002, Journal of Bone and Mineral Metabolism.

Five Years of Cenosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the First Two Years of the FREEDOM Extension

Jacques P. Brown, S. Cummings, E. Vittinghoff, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Relationship between trabecular vertebral body density and fractures: a quantitative definition of spinal osteoporosis.

J. Wergedal, C. Libanati, E. Schulz, 1988, Metabolism: clinical and experimental.

Romosozumab Reduces Incidence of New Vertebral Fractures Across Severity Grades Among Postmenopausal Women with Osteoporosis.

P. Geusens, F. Jakob, B. Langdahl, 2021, Bone.

Extensive modeling-based bone formation after 2 months of romosozumab treatment: Results from the FRAME clinical trial

Jacques P. Brown, R. Chapurlat, P. Chavassieux, 2020 .

Romosozumab Enhances Vertebral Bone Structure in Women With Low Bone Density

Graham M. Treece, A. Gee, A. Grauer, 2021, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Predicting Imminent Fractures in Patients With a Recent Fracture or Starting Oral Bisphosphonate Therapy: Development and International Validation of Prognostic Models

M. Javaid, B. Abrahamsen, D. Prieto-Alhambra, 2021, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Reproducibility of DXA in obese women.

T. Lohman, W. Howell, C. Libanati, 2002, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Serum fluoride and serum osteocalcin levels in response to a novel sustained-release monofluorophosphate preparation: Comparison with plain monofluorophosphate

A. Battmann, H. Resch, C. Libanati, 2005, Osteoporosis International.

Pharmacokinetic profile of a new fluoride preparation: Sustained-release monofluorophosphate

P. Bettica, C. Libanati, D. Baylink, 2004, Calcified Tissue International.

In postmenopausal women with osteoporosis, denosumab significantly improved trabecular bone score (TBS), an index of trabecular microarchitecture

J. Kaufman, M. Brandi, J. Zanchetta, 2012 .

Reproducibility of body measurements in very obese postmenopausal women.

T. Lohman, W. Howell, C. Libanati, 1999, Annals of the New York Academy of Sciences.

OP0100 Superior Gains in Bone Mineral Density and Estimated Strength at The Hip for Romosozumab Compared with Teriparatide in Women with Postmenopausal Osteoporosis Transitioning from Bisphosphonate Therapy: Results of The Phase 3 Open-Label Structure Study

A. Grauer, T. Keaveny, K. Engelke, 2016 .

Superior Gains in Bone Mineral Density (BMD) and Estimated Strength at the Hip for Romosozumab Compared With Teriparatide (TPTD) in Women With Postmenopausal Osteoporosis Transitioning From Bisphosphonate Therapy: Results of the Phase 3 Open-label STRUCTURE Study

Jacques P. Brown, H. Genant, T. Keaveny, 2016 .

Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis.

Jacques P. Brown, M. Brandi, E. Franek, 2013, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Detection of vertebral fractures in CT using 3D Convolutional Neural Networks pdf

Dirk Vandermeulen, David Robben, Joeri Nicolaes, 2019, CSI@MICCAI.

Multiple myeloma. Diagnostic clues in a patient presenting with incapacitating arthralgias.

C. Libanati, R. Goodman, 1997, Postgraduate medicine.

The increase in spinal bone density that occurs in response to fluoride therapy for osteoporosis is not maintained after the therapy is discontinued

M. Fischer, C. Libanati, D. Baylink, 2005, Osteoporosis International.

Mortality following fragility hip fracture in China: a record linkage study

Y. Li, A. Moayyeri, C. Libanati, 2023, Archives of Osteoporosis.

Fluoride therapy for osteoporosis: A review of dose response, duration of treatment, and skeletal sites of action

C. Libanati, E. Schulz, D. Baylink, 2007, Calcified Tissue International.

Healthcare costs associated with opportunistically identifiable vertebral fractures.

K. Olsen, B. Abrahamsen, C. Libanati, 2023, Bone.

Fracture Risk in Men and Women With Vertebral Fractures Identified Opportunistically on Routine Computed Tomography Scans and Not Treated for Osteoporosis: An Observational Cohort Study

K. Olsen, B. Abrahamsen, C. Libanati, 2023, JBMR plus.

Imminent fracture risk assessments in the UK FLS setting: implications and challenges

C. Cooper, M. Javaid, M. Charokopou, 2019, Archives of Osteoporosis.

Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial

J. S. San Martin, B. Clarke, J. Álvaro-Gracia, 2009 .

Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis.

Jacques P. Brown, M. Brandi, E. Franek, 2013, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density.

Jacques P. Brown, H. Genant, T. Fuerst, 2010, Bone.

Effects of romosozumab administration on trabecular and cortical bone assessed with quantitative computed tomography and finite element analysis

C. Graeff, G. Campbell, J. Peña, 2013 .

Towards Improved Identification of Vertebral Fractures in Routine Computed Tomography (CT) Scans: Development and External Validation of a Machine Learning Algorithm

D. Vandermeulen, T. Fuerst, C. Libanati, 2023, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Effects of denosumab on bone turnover markers in postmenopausal osteoporosis

S. Cummings, C. Christiansen, I. Reid, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.